Vectibix (panitumumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Vectibix (panitumumab) is a monoclonal antibody used in the treatment of cancer, particularly metastatic colorectal cancer (mCRC). It targets the epidermal growth factor receptor (EGFR), a protein present on the surface of certain cancer cells. Panitumumab binds to EGFR, preventing activation by natural growth factors, thereby inhibiting the signaling pathways that drive cell division and tumor growth.

The main distribution channels for Vectibix (panitumumab) include hospital pharmacies and online pharmacies. Hospital pharmacies are located within hospitals or healthcare facilities and provide medications to both inpatients and outpatients as part of comprehensive medical care. It is used in colorectal cancer treatment and other oncology applications by various end users, including hospitals, clinics, and ambulatory surgical centers.

Tariffs have impacted the vectibix market by increasing costs associated with imported monoclonal antibody manufacturing inputs and specialized biologic equipment. These effects are most evident in oncology hospitals across europe and asia pacific where advanced biologics are heavily utilized. Higher import duties have contributed to increased treatment costs for metastatic colorectal cancer therapies. Supply chain timelines have also been influenced by regulatory and customs procedures. However, tariffs are encouraging regional biologics manufacturing and improving long term supply resilience.

The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides vectibix (panitumumab) market statistics, including vectibix (panitumumab) industry global market size, regional shares, competitors with a vectibix (panitumumab) market share, detailed vectibix (panitumumab) market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. This vectibix (panitumumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vectibix (panitumumab) market size has grown strongly in recent years. It will grow from $1.37 million in 2025 to $1.48 million in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to approval for metastatic colorectal cancer, proven egfr inhibition efficacy, oncology specialist adoption, rising colorectal cancer incidence, advancement in targeted cancer drugs.

The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $2 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing cancer diagnostics, expansion into additional cancer therapies, rising oncology healthcare spending, improved patient stratification. Major trends in the forecast period include increased use of targeted egfr therapies, expansion of precision oncology treatments, rising biomarker based patient selection, hospital based monoclonal antibody adoption, combination therapy use in advanced cancers.

The growing prevalence of colorectal cancer is expected to drive the growth of the Vectibix (panitumumab) market in the coming years. Colorectal cancer is a type of cancer that originates in the colon or rectum, often developing from precancerous polyps. The increasing prevalence is linked to unhealthy lifestyle habits, including poor diet, lack of exercise, and obesity, which raise the risk of polyp formation and cancer progression. Vectibix (panitumumab) is a monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR), helping to slow tumor growth in patients with wild-type KRAS tumors and providing an effective treatment option for those who have not responded to conventional chemotherapy. For example, in February 2025, the American Cancer Society reported an estimated 154,270 new colorectal cancer cases in the U.S., up from 152,810 cases in 2024. Consequently, the rising prevalence of colorectal cancer is supporting the growth of the Vectibix (panitumumab) market.

The increasing demand for personalized medicine is also expected to drive the growth of the Vectibix (panitumumab) market. Personalized medicine customizes treatments and healthcare strategies based on the unique characteristics, needs, and preferences of each patient. Its rise is driven by advancements in genomic technologies, which allow precise identification of genetic variations and the delivery of tailored therapies. Vectibix is used in personalized medicine by targeting EGFR on cancer cells, providing customized treatment for patients with metastatic colorectal cancer whose tumors express wild-type EGFR, thereby optimizing therapeutic outcomes and minimizing side effects based on individual genetic profiles. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the growing demand for personalized medicine is contributing to the expansion of the Vectibix (panitumumab) market.

Key players in the Vectibix (panitumumab) market are focusing on developing advanced companion diagnostics to enable targeted therapies, enhance treatment efficacy, and ensure patient safety. Companion diagnostics are tests that provide critical information for the safe and effective use of a corresponding therapy. For instance, in October 2023, EntroGen Inc., a U.S.-based biotechnology company, received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This molecular diagnostic tool represents a major advancement in precision medicine for colorectal cancer (CRC) patients. It is the first real-time PCR-based test in the U.S. to receive premarket approval (PMA) and fully meet biomarker identification requirements for Vectibix. The kit accurately detects mutations in KRAS and NRAS exons 2, 3, and 4 with high sensitivity and specificity, enabling clinicians to identify patients most likely to benefit from Vectibix therapy, while minimizing unnecessary side effects and treatment costs.

Major companies operating in the vectibix (panitumumab) market are Amgen Inc.

North America was the largest region in the vectibix (panitumumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vectibix (panitumumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vectibix (panitumumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses vectibix (panitumumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vectibix (panitumumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vectibix (panitumumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
• 2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
• Companies Mentioned: Amgen Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.